Leerink Partnrs Issues Optimistic Forecast for JANX Earnings

Janux Therapeutics, Inc. (NASDAQ:JANX) – Stock analysts at Leerink Partnrs increased their Q2 2025 earnings estimates for Janux Therapeutics in a research note issued to investors on Monday, May 12th. Leerink Partnrs analyst J. La. Rosa now forecasts that the company will post earnings of ($0.47) per share for the quarter, up from their prior forecast of ($0.49). The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.38) per share. Leerink Partnrs also issued estimates for Janux Therapeutics’ Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($1.04) EPS, FY2025 earnings at ($2.43) EPS, FY2026 earnings at ($4.76) EPS, FY2027 earnings at ($5.42) EPS, FY2028 earnings at ($4.20) EPS and FY2029 earnings at ($2.01) EPS.

Several other analysts have also issued reports on the stock. Scotiabank dropped their price target on shares of Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a research report on Friday, February 28th. HC Wainwright reiterated a “buy” rating and set a $70.00 target price on shares of Janux Therapeutics in a research note on Monday, March 3rd. Finally, Wedbush restated an “outperform” rating and issued a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Janux Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $95.25.

Janux Therapeutics Price Performance

Shares of NASDAQ JANX opened at $22.62 on Wednesday. The business has a 50-day moving average of $28.89 and a 200-day moving average of $41.16. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of -19.33 and a beta of 3.24. Janux Therapeutics has a fifty-two week low of $22.48 and a fifty-two week high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%.

Hedge Funds Weigh In On Janux Therapeutics

Hedge funds have recently bought and sold shares of the company. RA Capital Management L.P. boosted its position in shares of Janux Therapeutics by 13.1% during the 4th quarter. RA Capital Management L.P. now owns 10,365,652 shares of the company’s stock worth $554,977,000 after acquiring an additional 1,200,000 shares in the last quarter. Paradigm Biocapital Advisors LP boosted its holdings in shares of Janux Therapeutics by 46.5% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 3,515,986 shares of the company’s stock valued at $188,246,000 after purchasing an additional 1,115,412 shares in the last quarter. Janus Henderson Group PLC increased its stake in shares of Janux Therapeutics by 41.2% in the 4th quarter. Janus Henderson Group PLC now owns 3,562,402 shares of the company’s stock valued at $190,617,000 after purchasing an additional 1,038,996 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in shares of Janux Therapeutics by 47.6% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,061,750 shares of the company’s stock worth $163,926,000 after buying an additional 986,750 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Janux Therapeutics by 596.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,109,978 shares of the company’s stock worth $59,429,000 after buying an additional 950,557 shares in the last quarter. 75.39% of the stock is owned by institutional investors.

Insider Buying and Selling at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 3,334 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $32.15, for a total transaction of $107,188.10. Following the completion of the sale, the insider now directly owns 82,139 shares in the company, valued at approximately $2,640,768.85. This represents a 3.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Ra Capital Management, L.P. bought 341,742 shares of Janux Therapeutics stock in a transaction dated Wednesday, March 5th. The shares were bought at an average cost of $30.64 per share, for a total transaction of $10,470,974.88. Following the completion of the acquisition, the director now owns 9,658,988 shares in the company, valued at $295,951,392.32. This represents a 3.67% increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 10,001 shares of company stock valued at $313,964 in the last ninety days. 8.10% of the stock is currently owned by corporate insiders.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.